Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Mink Therapeutics Inc (INKT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: INKT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $39
1 Year Target Price $39
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -71.86% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 69.75M USD | Price to earnings Ratio - | 1Y Target Price 39 |
Price to earnings Ratio - | 1Y Target Price 39 | ||
Volume (30-day avg) 3 | Beta 0.33 | 52 Weeks Range 4.56 - 76.00 | Updated Date 08/14/2025 |
52 Weeks Range 4.56 - 76.00 | Updated Date 08/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.46 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -111.9% | Return on Equity (TTM) -1238.98% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 71631632 | Price to Sales(TTM) - |
Enterprise Value 71631632 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.67 | Shares Outstanding 3985660 | Shares Floating 1016781 |
Shares Outstanding 3985660 | Shares Floating 1016781 | ||
Percent Insiders 74.4 | Percent Institutions 1.55 |
Upturn AI SWOT
Mink Therapeutics Inc
Company Overview
History and Background
Mink Therapeutics, Inc. is a biotechnology company founded in 2017. It focuses on developing cell therapies for cancer treatment. They went public in October 2021. Mink's initial focus has been on allogeneic, or 'off-the-shelf', cell therapies engineered with their proprietary CAR (chimeric antigen receptor) and IIT (innate immune therapy) technologies.
Core Business Areas
- Cell Therapy Development: Mink Therapeutics focuses on developing novel allogeneic cell therapies using its proprietary technology platforms for treating various types of cancer.
Leadership and Structure
Dr. Jennifer Filbey is the CEO. The company has a board of directors and a management team overseeing research, development, and operations.
Top Products and Market Share
Key Offerings
- ILT-CAR: Mink Therapeutics' primary therapeutic candidate, ILT-CAR, is designed to target and eliminate cancer cells by leveraging both innate and adaptive immune mechanisms. It is currently in early-stage clinical trials. Market share data is currently unavailable due to the early stage of development. Competitors include cell therapy companies like Kite Pharma, Novartis, and Bristol Myers Squibb in broader immunotherapy area.
Market Dynamics
Industry Overview
The cell therapy market is rapidly growing, driven by advances in gene editing and immunotherapy. It's characterized by high innovation and competition, with numerous companies developing novel cell-based cancer treatments.
Positioning
Mink Therapeutics is positioned as an innovator in the allogeneic cell therapy space, focusing on leveraging innate immunity to enhance efficacy and overcome limitations of traditional CAR-T therapies.
Total Addressable Market (TAM)
The global cell therapy market is projected to reach billions of dollars in the coming years. Mink is targeting specific cancers with high unmet needs, positioning it to capture a portion of this expanding market.
Upturn SWOT Analysis
Strengths
- Proprietary ILT-CAR technology platform
- Focus on allogeneic cell therapies (off-the-shelf)
- Experienced management team
- Novel approach leveraging innate immunity
Weaknesses
- Early-stage clinical development (high risk)
- Limited financial resources compared to larger competitors
- Dependence on successful clinical trial outcomes
- Company is small and relatively unknown in the market.
Opportunities
- Positive clinical trial data could significantly increase valuation
- Partnerships with larger pharmaceutical companies
- Expansion of ILT-CAR technology to other cancer types
- Potential for regulatory fast-track designations
Threats
- Clinical trial failures
- Competition from established cell therapy companies
- Regulatory hurdles
- Financial market volatility affecting funding availability
Competitors and Market Share
Key Competitors
- Gilead (GILD)
- Novartis (NVS)
- Bristol Myers Squibb (BMY)
Competitive Landscape
Mink faces competition from large pharmaceutical companies with established cell therapy programs. Its advantage lies in its novel technology and focus on innate immunity, which could differentiate its therapies.
Growth Trajectory and Initiatives
Historical Growth: Mink Therapeutics' growth has been focused on advancing its ILT-CAR technology through preclinical and early clinical stages.
Future Projections: Future growth is contingent on successful clinical trial outcomes and potential partnerships. Analyst estimates vary depending on the perceived probability of success.
Recent Initiatives: Recent initiatives include enrolling patients in clinical trials, presenting data at scientific conferences, and securing additional funding.
Summary
Mink Therapeutics is a high-risk, high-reward clinical-stage biotech company developing novel cell therapies. Their proprietary technology and focus on innate immunity offer potential advantages, but clinical trial success and adequate funding are crucial for future growth. The company needs to navigate regulatory hurdles and intense competition in the cell therapy market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data provided is based on publicly available information and may be subject to change. Investing in biotech companies carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mink Therapeutics Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2021-10-15 | President, CEO & Director Dr. Jennifer S. Buell Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 23 | Website https://minktherapeutics.com |
Full time employees 23 | Website https://minktherapeutics.com | ||
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab plus balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastro-esophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome. It is also developing MiNK-215, an IL-15 armored tumor stromal targeting the FAP-CAR-iNKT program to treat solid tumors and inflammation; and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for auto-immune diseases. The company has collaborations with Autonomous Therapeutics to target and treat metastatic tumors; and ImmunoScape, Inc. to discover and develop T-cell receptor therapies against targets in solid tumors. The company was formerly known as AgenTus Therapeutics, Inc. and changed its name to MiNK Therapeutics, Inc. in June 2021. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.